BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 37936713)

  • 21. Unfolded protein response signature unveils novel insights into breast cancer prognosis and tumor microenvironment.
    Zhou N; Kong D; Lin Q; Yang X; Zhou D; Lou L; Huang F
    Cancer Genet; 2023 Aug; 276-277():17-29. PubMed ID: 37343507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
    Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HGH1 and the immune landscape: a novel prognostic marker for immune-desert tumor microenvironment identification and immunotherapy outcome prediction in human cancers.
    Wu G; Dong Y; Hu Q; Ma H; Xu Q; Xu K; Chen H; Yang Z; He M
    Cell Cycle; 2023 Sep; 22(18):1969-1985. PubMed ID: 37811868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical implication and immunological landscape analyses of ANLN in pan-cancer: A new target for cancer research.
    Zhang L; Wei Y; He Y; Wang X; Huang Z; Sun L; Chen J; Zhu Q; Zhou X
    Cancer Med; 2023 Feb; 12(4):4907-4920. PubMed ID: 36030492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 26. Exploring the immunological role and prognostic potential of PPM1M in pan-cancer.
    Zeng R; Wang L; Zhang Y; Yang Y; Yang J; Qin Y
    Medicine (Baltimore); 2023 Mar; 102(12):e32758. PubMed ID: 36961170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy.
    Tu Z; Li K; Ji Q; Huang Y; Lv S; Li J; Wu L; Huang K; Zhu X
    BMC Cancer; 2023 Feb; 23(1):133. PubMed ID: 36759763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 29. Tubulin alpha-1b chain was identified as a prognosis and immune biomarker in pan-cancer combing with experimental validation in breast cancer.
    Wang Y; Li Y; Jing Y; Yang Y; Wang H; Ismtula D; Guo C
    Sci Rep; 2024 Apr; 14(1):8201. PubMed ID: 38589634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pan-cancer analysis reveals that G6PD is a prognostic biomarker and therapeutic target for a variety of cancers.
    Zeng T; Li B; Shu X; Pang J; Wang H; Cai X; Liao Y; Xiao X; Chong Y; Gong J; Li X
    Front Oncol; 2023; 13():1183474. PubMed ID: 37601657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
    Cao K; Ling X; Jiang X; Ma J; Zhu J
    Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.
    Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y
    Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of HMGB3 and its prognostic value in breast cancer.
    Zhou X; Zhang Q; Liang G; Liang X; Luo B
    Front Oncol; 2022; 12():1048921. PubMed ID: 36620553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pan-cancer characterization of immune-related NFIL3 identifies potential predictive biomarker.
    Fei Q; Zhang X; Wang S; Shu G; Yin G
    J Cancer; 2024; 15(5):1271-1286. PubMed ID: 38356719
    [No Abstract]   [Full Text] [Related]  

  • 35. Comprehensive Pan-cancer Analysis of CMPK2 as Biomarker and Prognostic Indicator for Immunotherapy.
    Luo J; Zhang Q; Wang S; Zheng L; Liu J; Zhang Y; Wang Y; Wang R; Xiao Z; Li Z
    Curr Cancer Drug Targets; 2024 Mar; ():. PubMed ID: 38486392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 37. Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of
    Zhang S; Xiong H; Yang J; Yuan X
    Front Mol Biosci; 2021; 8():792154. PubMed ID: 35155565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allograft inflammatory factor 1 is a potential diagnostic, immunological, and prognostic biomarker in pan-cancer.
    Liu X; Zhang D; Hu J; Xu S; Xu C; Shen Y
    Aging (Albany NY); 2023 Apr; 15(7):2582-2609. PubMed ID: 37014322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pan-Cancer Analyses Confirmed the Ferroptosis-Related Gene
    Lin Y; Dong Y; Liu W; Fan X; Sun Y
    Int J Gen Med; 2022; 15():2501-2513. PubMed ID: 35282646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.